Author Affiliations: Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass (Drs Lipper and Dover). Dr Arndt is a member of the JAMA Editorial Board and Editor of Archives of Dermatology.
Contempo Updates Section Editors: Thomas
C. Jefferson, MD, Contributing Editor; Stephen J. Lurie, MD, PhD, Fishbein
Recent advances in dermatologic therapy include the use of imiquimod
beyond its original use as a treatment for anogenital condylomata acuminata.
Another immunomodulating drug, tacrolimus, has been used topically to treat
a variety of dermatoses. New concepts in the management of toxic epidermal
necrolysis will also be discussed.
Imiquimod (Aldara, 3M Pharmaceuticals, St Paul, Minn), a novel immunomodulatory
imidazoquinolin heterocyclic amine, has shown potent antiviral and antitumor
action both experimentally and in recent clinical trials.1- 6
In clinical practice, the drug was approved by the Food and Drug Administration
for topical application as a treatment of anogenital condylomata acuminata,
and can be easily applied to affected areas by the patient at home, with 5%
imiquimod cream left on overnight (6-10 hours) and then washed off, used 3
days a week for 16 weeks or until all visible warts have disappeared.2
Lipper GM, Arndt KA, Dover JS. Recent Therapeutic Advances in Dermatology. JAMA. 2000;283(2):175-177. doi:10.1001/jama.283.2.175